#China #Suzhou #Autoimmune Diseases #HKeyBio #NHP in vitro model

HKeyBio Launches HKEY-NHP-onChip™ 1.1

HKeyBio, a prominent contract research organization (CRO) known for its work in autoimmune and allergic diseases, has recently launched its groundbreaking HKEY-NHP-onChip™ 1.1 model, heralded as the first-ever non-human primate (NHP) in vitro system aimed specifically at these medical conditions. This innovative platform promises multiple advantages, ranging from significant cost reductions to decreased reliance on animal testing, making it a game-changer in the field of biomedical research.

Transforming Drug Development

The HKEY-NHP-onChip™ 1.1 integrates sophisticated organoid technologies derived from non-human primates with a cutting-edge organ-on-chip design. This combination allows researchers to transition away from traditional in vivo animal studies and move towards more efficient high-throughput in vitro research methods. The importance of this shift cannot be overstated, as the drug development process for autoimmune diseases can take over a decade and often costs upwards of $2.6 billion. More crucially, this process is hampered by low success rates for clinical trials, primarily due to inadequate predictive power of existing preclinical models.

HKeyBio aims to address these issues head-on. By enabling a reduction in the costs of single experiments by a factor of ten to one hundred, the new model offers biotech companies an efficient solution that maintains scientific fidelity while exhausting fewer resources. Current statistics point to an impending challenge: the global market for autoimmune drugs is projected to skyrocket from $145 billion in 2024 to $218 billion by 2030, but the success rates of drug candidates continue to decline. HKeyBio is positioned to alleviate this bottleneck.

The NHP-Derived In Vitro Model System

The HKEY-NHP-onChip™ 1.1 benefits from a wealth of experience, having developed standardized, NHP-derived in vitro models built on decades of extensive in vivo experimentation. These models include various organoids—like intestinal and skin organoids—that yield high differentiation rates and create a realistic environment for immune-tissue interactions. As part of its multifaceted approach, HKeyBio has also established collaboration with esteemed hospitals to develop simultaneous human disease models, ensuring validation across species.

Enhancing Predictive Power and Reducing Variability

Not only does HKeyBio's new platform improve productivity, but it also aims to enhance validity in drug development. By building a comprehensive cross-validation system that includes several autoimmune diseases, the platform strives to improve predictive reliability significantly. The introduction of up to 80% reduction in animal usage and a marked decrease in variability—down to 15-25% from traditional rates of 30-50%—presents a compelling case for the adoption of this new research paradigm.

Future Roadmap and Strategic Vision

Looking ahead, HKeyBio has set an ambitious three-phase roadmap for the HKEY-NHP-onChip™ 1.1. Currently in the expansion stages, the focus is on validating twelve disease models, establishing a biobank of patient-derived organoids, and securing partnerships with more hospitals for clinical collaborations. The ultimate vision entails smart upgrades to the platform incorporating high-throughput automation and artificial intelligence to streamline research and enhance data generation.

This unique product marks a pivotal transformation for HKeyBio from merely being an expert in NHP in vivo research to establishing a comprehensive in vivo–in vitro integrated research platform that is characterized by both innovation and practicality. The company emphasizes that its mission is not simply about accumulating data but generating actionable insights that can empower decision-making processes in drug development.

Conclusion

The introduction of HKEY-NHP-onChip™ 1.1 is poised to redefine research methodologies within the pharmaceutical industry. HKeyBio's commitment to providing a sophisticated and efficient platform caters to the urgent needs of companies focusing on autoimmune and allergic diseases, paving the way for breakthroughs that can substantially shorten development timelines and enhance drug efficacy. With the landscape of biomedical research continuously evolving, HKeyBio's new technology could very well shape its future trajectory.

For more information, visit HKeyBio's official website.